Aurora Cannabis receives non-compliance notice from Nasdaq
Seeking Alpha News (Mon, 27-Mar 2:33 AM ET)
Aurora Provides Update on Nasdaq Listing
PRNewswire (Fri, 24-Mar 6:00 PM ET)
Aurora Cannabis Announces Filing of Preliminary Base Shelf Prospectus
PRNewswire (Fri, 17-Mar 5:15 PM ET)
News Direct (Thu, 9-Mar 9:43 AM ET)
Aurora Launches New Medical Flower Product, Valour - Designed for Veterans, by Veterans
PRNewswire (Thu, 2-Mar 7:10 AM ET)
Cannabis Investors Focus on E-Commerce and Financial Results
Globe Newswire (Wed, 22-Feb 8:30 AM ET)
Aurora and MedReleaf Australia Launch new Medical Cannabis Brand - CraftPlant
PRNewswire (Wed, 22-Feb 7:10 AM ET)
Aurora Cannabis Announces Fiscal 2023 Second Quarter Results
PRNewswire (Thu, 9-Feb 4:10 PM ET)
Aurora Cannabis to Host Second Quarter Fiscal Year 2023 Investor Conference Call
PRNewswire (Thu, 26-Jan 7:00 AM ET)
PRNewswire (Wed, 4-Jan 7:00 AM ET)
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
Aurora Cannabis - Common Shares trades on the NASDAQ stock market under the symbol ACB.
As of March 27, 2023, ACB stock price declined to $0.69 with 1,296,413 million shares trading.
ACB has a beta of 1.41, meaning it tends to be more sensitive to market movements. ACB has a correlation of 0.12 to the broad based SPY ETF.
ACB has a market cap of $235.28 million. This is considered a Small Cap stock.
Last quarter Aurora Cannabis - Common Shares reported $46 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.09.
In the last 3 years, ACB stock traded as high as $19.68 and as low as $.66.
The top ETF exchange traded funds that ACB belongs to (by Net Assets): MJ, ONEQ, DFIC, DFIS, DFAI.
ACB has underperformed the market in the last year with a price return of -82.9% while the SPY ETF lost -10.6%. ACB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.6% and -6.4%, respectively, while the SPY returned +3.9% and +3.1%, respectively.
ACB support price is $.68 and resistance is $.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACB stock will trade within this expected range on the day.